摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

p-nitrobenzyl 2-bromo-2-methylpropionate | 84208-33-3

中文名称
——
中文别名
——
英文名称
p-nitrobenzyl 2-bromo-2-methylpropionate
英文别名
4-nitrobenzyl α-bromoisobutyrate;p-nitrobenzyl α-bromoisobutyrate;p-nitrobenzyl-2-bromo-2-methyl propionate;(4-Nitrophenyl)methyl 2-bromo-2-methylpropanoate
p-nitrobenzyl 2-bromo-2-methylpropionate化学式
CAS
84208-33-3
化学式
C11H12BrNO4
mdl
——
分子量
302.125
InChiKey
PWQRRDRMTKNUMF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    377.6±22.0 °C(Predicted)
  • 密度:
    1.508±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    72.1
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:5fb342b98ed06f7fb766298e4e56d03e
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives.
    摘要:
    在磺扎西丁的化学修饰过程中,从顺式-1-(2,4-二甲氧基苄基)-4-甲氧羰基-3-酞酰亚胺基-2-氮杂环丁酮(2)出发,合成了3-[2-(2-氨基噻唑-4-基)-(Z)-2-(取代氧亚胺基)乙酰胺基]-4-甲氧羰基-2-氮杂环丁酮-1-磺酸。这些新的4-取代衍生物对革兰氏阴性菌的抗菌活性比相应的4-未取代化合物更强,其中具有3,4-顺式立体化学结构的衍生物比反式异构体更活跃,尤其对铜绿假单胞菌和一些产生β-内酰胺酶的细菌更为有效。研究了用于制备2的环加成反应的报道程序;通过使用20%过量的三乙胺,可以很容易地以72%的产率得到无色晶体2。在这种环加成反应中形成β-内酰胺的可能中间体——酰基亚胺盐(6)被分离为晶体,并通过与1,8-二氮杂双环[5.4.0]-7-十一碳烯处理转化为β-内酰胺。
    DOI:
    10.1248/cpb.32.2646
  • 作为产物:
    描述:
    对硝基苯甲醇2-溴-2-甲基丙酰溴吡啶 作用下, 以 乙醚 为溶剂, 反应 5.0h, 以29.6 g的产率得到p-nitrobenzyl 2-bromo-2-methylpropionate
    参考文献:
    名称:
    Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives.
    摘要:
    在磺扎西丁的化学修饰过程中,从顺式-1-(2,4-二甲氧基苄基)-4-甲氧羰基-3-酞酰亚胺基-2-氮杂环丁酮(2)出发,合成了3-[2-(2-氨基噻唑-4-基)-(Z)-2-(取代氧亚胺基)乙酰胺基]-4-甲氧羰基-2-氮杂环丁酮-1-磺酸。这些新的4-取代衍生物对革兰氏阴性菌的抗菌活性比相应的4-未取代化合物更强,其中具有3,4-顺式立体化学结构的衍生物比反式异构体更活跃,尤其对铜绿假单胞菌和一些产生β-内酰胺酶的细菌更为有效。研究了用于制备2的环加成反应的报道程序;通过使用20%过量的三乙胺,可以很容易地以72%的产率得到无色晶体2。在这种环加成反应中形成β-内酰胺的可能中间体——酰基亚胺盐(6)被分离为晶体,并通过与1,8-二氮杂双环[5.4.0]-7-十一碳烯处理转化为β-内酰胺。
    DOI:
    10.1248/cpb.32.2646
点击查看最新优质反应信息

文献信息

  • 1-Sulfo-2-oxoazetidine derivatives and their production
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04550105A1
    公开(公告)日:1985-10-29
    Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula --OR.sub.5, ##STR2## or --S--S--R.sub.5 wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.
    揭示了一般式为:其中R₁为氨基、酰化氨基或保护氨基,X为氢或甲氧基,R'为氢、R或R⁴,其中R为有机残基,通过其中的碳原子连接到氮杂环上,R⁴为叠氮基、卤素、氨基(可选地酰化)或具有如下结构的基团--OR₅,或--S--S--R₅,其中R₅为有机残基,n为0、1或2,以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性,并且作为人类和驯养动物的药物具有价值。
  • 1-sulfo-2-oxoazetidine derivatives and their production
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04782147A1
    公开(公告)日:1988-11-01
    Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.
    揭示了一般式化合物:##STR1## 其中 R.sub.1 是氨基、酰化氨基或保护氨基,X 是氢或甲氧基,而 R' 是氢、R 或 R.sup.4,其中 R 是通过其中的一个碳原子连接到环的有机残基,而 R.sub.4 是偶氮基、卤素、氨基(可选地酰化)或式 ##STR2## 其中 R.sub.5 是有机残基,n 为 0、1 或 2,以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性,并且作为人类和驯化动物的药物具有价值。
  • Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid
    申请人:Hoffmann-La Roche Inc.
    公开号:US04652651A1
    公开(公告)日:1987-03-24
    The manufacture of 1-sulpho-2-oxazetidine derivatives of the formula ##STR1## in which Het is an optionally amino-substituted, 5- or 6-membered, aromatic heterocycle containing 1 or 2 nitrogen atoms and optionally also an oxygen or sulphur atom, R.sup.1 is hydrogen, lower alkyl, phenyl-lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, phenyl-lower-alkoxycarbonyl-lower alkyl, nitrophenyl-lower-alkoxycarbonyl-lower alkyl or carboxy-lower alkyl and R.sup.2 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxycarbonyl, lower alkanoyloxy-lower alkyl, lower alkoxycarbonyl-lower alkenyl, hydroxyiminomethyl, lower alkoxyiminomethyl, carbamoyl, carbamoyl-lower alkenyl or carbamoyloxy-lower alkyl, the group .dbd.NOR.sup.1 being present at least partially in the syn-form, in racemic form or in the form of the 3S-enantiomer, and of readily hydrolyzable esters and pharmaceutically compatible salts of these compounds, by acylating a compound of the formula ##STR2## in which R.sup.20 equals R.sup.2 or can also represent a 2,2-dimethyl-1,3-dioxolan-4-yl group and R.sup.3 is hydrogen or sulpho, or a salt thereof with a thioester of the formula ##STR3## in which Het is as above and R.sup.10 has any of the values of R.sup.1 except carboxy-lower alkyl, and can also represent a tri-lower alkyl-silyl-lower-alkoxycarbonyl-lower alkyl group or a carboxy-lower alkyl group converted into a readily hydrolyzable ester group, and the group .dbd.NOR.sup.10 is present at least partially in the syn-form, and carrying out subsequent steps (N-sulphonation, conversion of R.sup.20 into R.sup.2, R.sup.10 into R.sup.1), some of which are optional. The invention also provides certain novel products of formula I and benzthiazolyl thioesters of formula III per se and the preparation of the benzthiazolyl thioesters by esterifying corresponding carboxylic acids. Finally, the invention provides a process for the preparation of carboxylic acids in which R.sup.1 is t-alkoxycarbonylmethyl. The compounds of formula I have antimicrobial activity.
    该专利描述了一种制备1-磺酸-2-噁唑环丙烷衍生物的方法,其化学式为##STR1##其中Het是一个含有1或2个氮原子和可能还有一个氧原子或硫原子的可选氨基取代的5或6元芳香杂环,R.sup.1是氢、低烷基、苯基-低烷基、低烷酰、低烷氧羰基、低烯基-低烷基、低烷氧羰基-低烷基、苯基-低烷氧羰基-低烷基、硝基苯基-低烷氧羰基-低烷基或羧基-低烷基,R.sup.2是氢、低烷基、低烯基、低炔基、低烷氧羰基、低烷酰氧基-低烷基、低烷氧羰基-低烯基、羟基亚胺甲基、低烷氧亚胺甲基、氨甲酰基、氨甲酰基-低烯基或氨甲酰氧基-低烷基,.dbd.NOR.sup.1基团至少部分以syn-形式存在,是外消旋形式或3S-对映体形式,以及这些化合物的易水解酯和药用兼容盐的制备方法。
  • 1-sulfo-2-oxozetidine derivatives and their product ion
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04822788A1
    公开(公告)日:1989-04-18
    Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmeceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.
    本发明涉及一般式为:##STR1##的化合物,其中R.sub.1是氨基,酰化氨基或保护氨基基团,X是氢或甲氧基,R'是氢,R或R.sup.4,其中R是通过其中的一个碳原子连接到氮杂四元环上的有机残基,R.sub.4是偶氮基,卤素,氨基(可以选择性地酰化)或式子##STR2##中的基团,其中R.sub.5是有机残基,n为0、1或2,以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性,是人类和家畜的有价值的药物。
  • 1-Sulfo-2-oxoazetidine derivatives, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP0053816A1
    公开(公告)日:1982-06-16
    A 1-sulfo-2-oxoazetidine derivative of formula wherein R is a residue derived from an organic compound by removal of one hydrogen atom attached to a carbon atom thereof; R' is an amino group which may optionally be , acylated or protected; X is hydrogen or methoxy, and methods of producing said compound (I) which may be written as follows or wherein the symbols have the same meanings as respectively defined above. The compound (I) has improved antimicrobial and β-lactamase-inhibitory activities and is of value as drugs for human beings and domesticated animals.
    一种 1-磺基-2-氧代氮杂环丁烷衍生物,其式中,R 是有机化合物的残基,通过去除连接到其碳原子上的一个氢原子而得到;R'是氨基,可任选被酰化或保护;X 是氢或甲氧基,以及生产所述化合物 (I) 的方法,其可如下写法或其中的符号分别具有与上述定义相同的含义。 该化合物 (I) 具有更好的抗菌活性和β-内酰胺酶抑制活性,具有作为人类和驯养动物药物的价值。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐